



NEONATAL




CLINDAMYCIN

This document should be read in conjunction with this [DISCLAIMER](#)

Restricted: Requires Microbiologist review within 24 hours of initiation

| Presentation | Ampoule: 600mg/4mL = 150mg/mL | | | | | | | | | | | | | | | | | | | | | | | | | |
|-----------------------------------|--|----------------------------------|----------------------|-------------|------------------|------------|-----------|------------|----------------|----------|------------|---------------|----------------|----------|------------|----------------|-----------|------------|---------------|-------------|----------|------------|----------------|----------|------------|---------------|
| Classification | Lincosamide antibiotic | | | | | | | | | | | | | | | | | | | | | | | | | |
| Indication | Infection due to susceptible organisms | | | | | | | | | | | | | | | | | | | | | | | | | |
| Dose | <p><u>Infection due to susceptible organisms</u></p> <p>IV/Oral:</p> <table border="1"> <thead> <tr> <th><u>Corrected Gestational Age</u></th> <th><u>Postnatal Age</u></th> <th><u>Dose</u></th> <th><u>Frequency</u></th> </tr> </thead> <tbody> <tr> <td rowspan="2">< 30 weeks</td> <td>≤ 28 days</td> <td>5-7.5mg/kg</td> <td>Every 12 hours</td> </tr> <tr> <td>>28 days</td> <td>5-7.5mg/kg</td> <td>Every 8 hours</td> </tr> <tr> <td rowspan="2">30 to 36 weeks</td> <td>≤14 days</td> <td>5-7.5mg/kg</td> <td>Every 12 hours</td> </tr> <tr> <td>> 14 days</td> <td>5-7.5mg/kg</td> <td>Every 8 hours</td> </tr> <tr> <td rowspan="2">37-44 weeks</td> <td>≤ 7 days</td> <td>5-7.5mg/kg</td> <td>Every 12 hours</td> </tr> <tr> <td>> 7 days</td> <td>5-7.5mg/kg</td> <td>Every 8 hours</td> </tr> </tbody> </table> | <u>Corrected Gestational Age</u> | <u>Postnatal Age</u> | <u>Dose</u> | <u>Frequency</u> | < 30 weeks | ≤ 28 days | 5-7.5mg/kg | Every 12 hours | >28 days | 5-7.5mg/kg | Every 8 hours | 30 to 36 weeks | ≤14 days | 5-7.5mg/kg | Every 12 hours | > 14 days | 5-7.5mg/kg | Every 8 hours | 37-44 weeks | ≤ 7 days | 5-7.5mg/kg | Every 12 hours | > 7 days | 5-7.5mg/kg | Every 8 hours |
| <u>Corrected Gestational Age</u> | <u>Postnatal Age</u> | <u>Dose</u> | <u>Frequency</u> | | | | | | | | | | | | | | | | | | | | | | | |
| < 30 weeks | ≤ 28 days | 5-7.5mg/kg | Every 12 hours | | | | | | | | | | | | | | | | | | | | | | | |
| | >28 days | 5-7.5mg/kg | Every 8 hours | | | | | | | | | | | | | | | | | | | | | | | |
| 30 to 36 weeks | ≤14 days | 5-7.5mg/kg | Every 12 hours | | | | | | | | | | | | | | | | | | | | | | | |
| | > 14 days | 5-7.5mg/kg | Every 8 hours | | | | | | | | | | | | | | | | | | | | | | | |
| 37-44 weeks | ≤ 7 days | 5-7.5mg/kg | Every 12 hours | | | | | | | | | | | | | | | | | | | | | | | |
| | > 7 days | 5-7.5mg/kg | Every 8 hours | | | | | | | | | | | | | | | | | | | | | | | |
| Dose Adjustment | Increase dosing interval in patients with significant liver dysfunction. | | | | | | | | | | | | | | | | | | | | | | | | | |
| Monitoring | Hepatic function, gastrointestinal status, full blood count and renal function during prolonged treatment | | | | | | | | | | | | | | | | | | | | | | | | | |
| Guidelines & Resources | Sepsis Calculator | | | | | | | | | | | | | | | | | | | | | | | | | |
| Compatible Fluids | Glucose 5% , Sodium chloride 0.9% | | | | | | | | | | | | | | | | | | | | | | | | | |

| | |
|--------------------------|---|
| Preparation | <p>IV: available from CIVAS (KEMH & PCH)</p> <p>Take 1mL (150mg) and add 29mL of compatible fluid. Concentration is 150mg/30mL Final Concentration = <u>5mg/mL</u></p> |
| Administration | <p>IV: Infuse over 30 to 60 minutes</p> |
| Adverse Reactions | <p>Common: Nausea, vomiting, abdominal cramps, diarrhoea, rash Serious: Pseudomembranous colitis, arrhythmias if administered too quickly</p> |
| Storage | <p>Check Brand for Storage Details Dalacin C®: Refrigerate – do not freeze. Store at 2 to 8 °C. Clindamycin DBL, Mylan®: store below 25 °C.</p> |
| Notes | <p>Discontinue if severe diarrhoea develops</p> <p>Diarrhoea, colitis and pseudomembranous colitis have been reported and may begin up to several weeks after cessation of therapy</p> <p>Some brands of clindamycin injection contain benzyl alcohol which has been associated with serious adverse events including “gaspig” syndrome in neonates</p> |
| References | <p>Truven Health Analytics. Clindamycin. In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2019 [cited 2019 Aug28]. Available from: https://neofax.micromedexsolutions.com/</p> <p>Society of Hospital Pharmacists of Australia. Clindamycin. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2019 [cited 2019 Oct 3]. Available from: http://aidh.hcn.com.au</p> |

| | | | |
|---|---|-------------------|----------|
| Document owner: | Head of Department - Neonatology | | |
| Author / Reviewer: | KEMH & PCH Pharmacy / Neonatology Directorate | | |
| Date first issued: | November 2008 | Version: | 3.0 |
| Last reviewed: | October 2019 | Next review date: | Oct 2022 |
| Endorsed by: | Neonatal Directorate Management Group | Date: | Oct 2019 |
| Standards Applicable: | NSQHS Standards: 1  Governance 3  Infection Control 4  Medication Safety; | | |
| Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from the WNHS website. | | | |

© Department of Health Western Australia 2019